AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

Morphological profiling allows accurate identification of cell types in dense iPSC-derived cultures, allowing its use for quality control and differentiation monitoring.